VN-100 Ph1/2
Phase 1
Completed
- Conditions
- Prophylaxis of influenza infection
- Registration Number
- JPRN-jRCT2080222050
- Lead Sponsor
- DAIICHISANKYO Co.,Ltd.
- Brief Summary
As a result of the immunogenicity and safety of VN-100 in healthy adults and elderly, a good increase in antibody titer and safety were confirmed. The immunogenicity of VN-100 with 6 micro g, 9 micro g, and 15 micro g was similar to subcutaneous influenza HA vaccine.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 600
Inclusion Criteria
Healthy adult Japanese volunteers
Exclusion Criteria
1) Subjects with history of seasonal influenza in the past 6 months
2) Subjects with history of seasonal influenza vaccination in the past 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method